Skip to main content

Educational content only. Not a substitute for medical advice. Always consult a qualified clinician.

Healthy Mango
ENES

Guides

Melanocortin biology

Four melanocortin receptor subtypes (MC1R–MC5R) sit at the intersection of pigmentation, sexual response, appetite regulation, and inflammation. Understanding which peptide targets which receptor is the foundation for reading everything from Melanotan to Vyleesi.

9 minute read · Last reviewed 2026-07-13

One hormone, five receptors, five different jobs

The melanocortin system is one of the more elegant examples of receptor-family specialisation in human endocrinology. A single parent hormone — pro-opiomelanocortin (POMC) — is cleaved into several peptide fragments including α-melanocyte-stimulating hormone (α-MSH), β-MSH, γ-MSH, ACTH and β-endorphin. Those fragments engage a family of five G-protein-coupled receptors (MC1R through MC5R), each expressed on different tissues and driving different physiological effects. MC1R is on melanocytes and controls pigmentation. MC2R is on adrenal cortex and mediates the ACTH signal for cortisol release. MC3R and MC4R are central nervous system receptors involved in appetite regulation and sexual response. MC5R is on sebaceous and exocrine glands. Every synthetic melanocortin peptide in this catalog — Melanotan I, Melanotan II, PT-141 — works on some subset of this receptor family, and understanding which receptors each engages is the foundation for reading the entire class.

MC1R and the pigmentation axis

MC1R activation on melanocytes shifts the biosynthetic balance from pheomelanin (the reddish-yellow pigment) toward eumelanin (the brown-black pigment). Eumelanin is the more photoprotective form — it absorbs UV radiation more effectively and dissipates the energy as heat rather than passing it to underlying DNA. This is the mechanism behind the melanocortin-based tanning peptides and behind the approved therapeutic use of afamelanotide (Scenesse) in erythropoietic protoporphyria. EPP is a rare inherited disorder in which patients experience severe painful reactions to sunlight because they lack normal photoprotection; afamelanotide's MC1R-driven eumelanin shift restores usable sun tolerance. That approval — EMA 2014, FDA 2019 — is a genuine rare-disease drug story. The grey-market cosmetic-tanning use of Melanotan I and Melanotan II uses the same MC1R mechanism but at unauthorised doses and delivery formats, and multiple national regulators including the UK MHRA have specifically warned against it.

MC4R, sexual response, and the accidental observation

The most consequential single observation in this receptor family came from studies of Melanotan II — a synthetic α-MSH analogue designed at the University of Arizona in the 1990s as a research tool for pigmentation. During early human tanning studies, investigators noticed that male participants developed spontaneous erections. That accidental observation reframed the entire programme, revealing that central MC4R (and to a lesser extent MC3R) activation engages the hypothalamic circuitry of appetitive sexual desire. Palatin Technologies licensed a structurally-refined variant of the compound (bremelanotide, later PT-141) and developed it into an FDA-approved treatment for hypoactive sexual desire disorder in premenopausal women (Vyleesi, 2019-06-21). The earlier intranasal male-ED phase-3 programme was discontinued for transient blood-pressure elevation — a class effect of central melanocortin activation — but the subcutaneous reformulation succeeded. The mechanistic story from Melanotan II to Vyleesi is one of the cleanest examples of accidental-observation-becomes-drug in modern pharmacology.

MC3R/MC4R and appetite regulation

Central MC4R is one of the most important nodes in the neural regulation of appetite. Loss-of-function mutations in MC4R are the most common single-gene cause of severe childhood-onset obesity in humans — a genetic discovery that put MC4R at the centre of obesity research. The FDA has approved setmelanotide (Imcivree) as a targeted MC4R agonist for specific rare monogenic obesities including POMC deficiency, PCSK1 deficiency, and Bardet-Biedl syndrome. In the research-peptide space, the anorectic (appetite-suppressing) effects of Melanotan II reflect this same MC4R pathway — one of the reasons users of Melanotan II frequently report reduced appetite as a side effect. It also explains why compounds that activate MC4R broadly (Melanotan II) tend to produce nausea more consistently than compounds designed for selective sexual-response effects (PT-141): the two effects share a common central-melanocortin signal at different points along the receptor-crosstalk pathway.

KPV and the anti-inflammatory melanocortin

Not all melanocortin activity is about pigmentation or appetite. The C-terminal tripeptide fragment of α-MSH — Lys-Pro-Val, known as KPV — retains the anti-inflammatory activity of the parent hormone while shedding most of the receptor-binding-related effects. KPV engages the NF-κB inflammatory pathway (specifically by inhibiting the nuclear translocation of NF-κB), reducing TNF-α, IL-6 and IL-1β signalling in inflamed tissue. That mechanism makes KPV an inflammation-suppressive peptide rather than a pigmentation or sexual-response one, and it is the reason KPV appears in tissue-repair blends (Aura, Klow) where inflammation control complements collagen synthesis and vascular repair. Kannengiesser 2008 characterised KPV's activity in the DSS colitis model as a topically active anti-inflammatory. The peptide represents a genuine editorial curiosity — the same POMC-derived family that gives us tanning and sexual-response peptides also gives us this small, focused anti-inflammatory fragment.

Common questions

Are Melanotan I, Melanotan II, and PT-141 the same molecule?

No — they are structurally related α-MSH analogues with different receptor selectivity and different regulatory identities. Melanotan I (afamelanotide) is a linear tridecapeptide with MC1R-favoured activity; it is FDA-approved as Scenesse for erythropoietic protoporphyria. Melanotan II is a cyclic heptapeptide with broad activity at MC1R, MC3R, MC4R and MC5R; it has no approved product anywhere and is the subject of specific regulator warnings. PT-141 (bremelanotide) is structurally almost identical to Melanotan II except for the C-terminal chemistry (amide vs free acid), which shifts selectivity toward MC4R; it is FDA-approved as Vyleesi for HSDD in premenopausal women. Same peptide family; three different molecules; three different regulatory positions.

Why do melanocortin agonists sometimes raise blood pressure?

Central melanocortin activation increases sympathetic outflow — a well-characterised class effect. This is why the earlier intranasal PT-141 phase-3 program for male erectile dysfunction was discontinued (dose-related transient blood-pressure elevations) and why Vyleesi carries a label contraindication for uncontrolled hypertension and known cardiovascular disease. The effect is more prominent with higher plasma peaks; the subcutaneous 1.75 mg Vyleesi formulation was selected in part because its pharmacokinetics reduced the peak-to-trough excursion compared to the intranasal formulation. Grey-market use of Melanotan II inherits this cardiovascular signal without the label monitoring framework — one of the reasons regulator warnings emphasise the cosmetic-use context.

What is the mole (naevus) monitoring concern?

MC1R activation drives melanocyte activity, and pre-existing melanocytic naevi may darken or change appearance during use of any MC1R-active compound. Case reports have documented melanoma diagnoses following naevus change during Melanotan II use (Cardones 2009 and follow-up literature). Case reports do not prove that the compound causes melanoma at scale, but they do establish a specific rationale for baseline and periodic dermatological examination during use. This is why the Scenesse (afamelanotide) label requires clinician-supervised dermatological monitoring, and why the same concern applies to grey-market Melanotan use — where the monitoring is typically not built into the practice framework.

References

Links open external, peer-reviewed sources. Healthy Mango does not host trial data.

Related on Healthy Mango

Continue exploring

Editorial paths through the library. Pick one and follow the trail.

Question

Related questions

Other questions that touch the same biology, evidence, or laboratory concepts.